Publication of Supplemental Prospectus Following a routine technical update in June 2014 of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following supplemental prospectus has been approved by the UK Listing Authority and is available for viewing: Supplemental Prospectus for the AstraZeneca PLC U.S.$5,000,000,000 Euro Medium Term Note Programme (the "Supplemental Prospectus") The Supplemental Prospectus should be read in connection with, and forms part of, the base prospectus dated 24 June 2014 prepared by the Company in connection with the EMTN programme (the "Base Prospectus"). To view the full Supplemental Prospectus, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rns/2358X_-2014-11-17.pdf To view the full Base Prospectus, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rns/4351K_1-2014-6-24.pdf A copy of the Supplemental Prospectus will shortly be submitted to the National Storage Mechanism and will be available for inspection at: http://www.morningstar.co.uk/uk/NSM A C N Kemp Company Secretary 17 November 2014
Publication of Supplementary Prospectus
| Source: AstraZeneca PLC